查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
家庭输液治疗市场：2023年至2028年预测
市场调查报告书
商品编码
1410089

家庭输液治疗市场：2023年至2028年预测

Home Infusion Therapy Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年全球家庭输液治疗市场规模为327.81亿美元。

预计家庭输液治疗市场将在整个预测期内稳定成长。家庭输液只是通常作为门诊手术在家中向患者提供的众多药物治疗之一。大多数这些药物必须透过针头或导管输送，这个过程称为输注。与家庭输液治疗相关的多重好处和增加的不动障碍是家庭输液治疗市场的主要成长动力。此外，不断上升的医院感染率和鼓励家庭治疗的政府法规预计将进一步推动家庭输液治疗市场。

家庭输液治疗的多种相关益处

居家输液治疗为患者带来了广泛的好处，从而促进了家庭输液治疗的采用并促进了家庭输液治疗市场的发展。患者对居家输液治疗的满意度很高，研究表明，在家病患比住院病患有更好的临床结果。根据您的个人医疗保健计划，它可能比在医院或诊所获得相同的服务便宜。此外，Evernorth Health Services 发现 78% 的客户表示，他们「非常」或「有些」愿意采用其他类型的护理，例如让临床医生上门服务。近年来，对更多服务的需求不断增加护理方法方面的灵活性和选择。据信，患者对居家照护的倾向以及相关的好处将推动家庭输液治疗市场的发展。

行动障碍增加

限制身体活动的不动障碍病例数量不断增加，显示对家庭输液治疗的需求不断增长。例如，有13亿重度身障者。根据世界卫生组织 2023 年 3 月发布的最新资讯，这相当于我们六分之一的人，即世界人口的 16%。据世界卫生组织称，残障人士找到方便且负担得起的交通途径的难度是正常人的 15 倍。因此，这些行动障碍预计将对家庭输液治疗市场产生积极影响，因为它为患者提供了便利的家庭环境。

需要缩短住院时间

居家输液治疗有助于缩短住院时间。据世界卫生组织称，每 100 名急诊医院患者中，高所得国家有 7 名患者，中低收入国家有 15 名患者在住院期间预计会感染至少 1 例医疗保健相关感染疾病(HAI)。 。平均每 10 名受影响者就会死于 HAI。世界卫生组织 2022 年的一项研究发现，超过一半的伴有器官衰竭的脓毒症病例在成人加护病房接受治疗，并且在医院接受治疗的脓毒症患者中约有四分之一与医疗保健有关。据透露。这种医院感染带来了问题，并正在推动家庭输液治疗市场的采用。

市场机会

上述成长动力显示家庭输液治疗市场存在巨大机会。此外，政府法规也为居家输液治疗市场创造了成长机会。例如，2021 年，医疗保险和医疗补助服务中心 (CMS) 通过了新法规，扩大了家庭输液治疗的覆盖范围，除了治疗本身之外，还涵盖各种相关的护理和监测服务。此外，Eitan Medical 还推出了 Avoset(TM)，这是一种最连网型的连接输液多疗法门诊输液系统，正在彻底改变急性后护理和专业输液治疗。此外，家庭输液治疗的监管核准将进一步推动家庭输液治疗市场并提供进入机会。例如，抗癌药物家庭注射疗法于2020年6月获得ASCO董事会核准。

市场抑制因素

有几个复杂的因素可能会限製家庭输液治疗市场。例如，家庭输液药局、患者、医生、出院计划人员、健康保险和其他相关人员必须密切合作才能完成这个过程，因为它可能是一个复杂的生态系统。由于相关人员众多，断开连接的资料可能会带来严重问题，并导致各种规定、管理和/或编码问题。例如，医生通常会提交事先核准请求和处方申请，这些请求和处方索赔是单独透过计划的。

预计北美将大幅成长

预计在预测期内，北美地区将在家庭输液治疗市场中占据重要份额。造成这一份额的因素包括鼓励家庭输液治疗的有利政府法规，以及不活动的增加、癌症等慢性疾病和人口老化。例如，12.1% 的美国成年人患有行动障碍，导致行走或爬楼梯变得极其困难，而最近的 CDC资料显示，12.8% 的美国成年人在集中註意力、记忆或做决定方面存在明显困难。此外，Baxter 和 Braun Melsungen AG 等市场参与者预计将进一步推动该地区的家庭输液治疗市场。

家庭输液治疗市场参与者

百特国际是一家总部位于美国的医疗保健公司，提供急性、营养、肾臟、医院和外科护理产品组合。该公司提供预混合静脉注射药物和注射药物组合，以满足患者的需求。

门诊手术中心、聘用医生网络、两家 HMO 和 15 家医院均属于 McLaren Healthcare 的一部分。医疗保健认证联合委员会 (JCAHO) 和社区健康认证计划 (CHAP) 均对麦克拉伦的家庭输液服务进行了认证。

新兴市场的主要发展

  • 2022 年 4 月，AméricSource Bergon (AB) 启动了一项计划，帮助医院和健康系统推出家庭输液服务线。这将加强家庭输液治疗的专案策略、业务运作和物流。
  • 2021 年 8 月，一家专门从事家庭输液的新公司 HealthIV推出，以抑制脱水和宿醉。
  • 2021年11月，医院临床血液肿瘤研究所（ICMHO）针对固态器官癌症患者启动了免疫治疗家庭输液计画和免疫治疗。进行定期检查、在患者家中给药并提供健康教育。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章家庭输液治疗市场：副产品

  • 介绍
  • 点滴帮浦组
  • 配件及消耗品

第六章家庭输液治疗市场：依应用分类

  • 介绍
  • 完全肠外营养
  • 抗感染疾病治疗
  • 经肠营养
  • 水化疗法
  • 化疗
  • 静脉注射免疫球蛋白/特殊药物
  • 其他用途

第七章家庭输液治疗市场：依给药途径

  • 介绍
  • 肌肉注射
  • 皮下的
  • 硬膜外

第八章家庭输液治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞赛矩阵

第十章 公司简介

  • Braun Melsungen AG
  • Baxter International
  • Becton Dickinson and Companies
  • Catholic Health Initiatives
  • Community Surgical Supply
  • Eli Lilly and Company
  • Fresenius Kabi
  • ICU Medical Inc.
  • McKesson Medical-Surgical Inc.
  • McLaren Health Care
简介目录
Product Code: KSI061615770

The global home infusion therapy market was valued at US$32.781 billion in 2021.

The home infusion therapy market is anticipated to grow at a steady pace throughout the forecast period. Home infusion is just one of the many pharmaceutical treatments that are generally offered to patients in their homes as outpatient care. The bulk of these medications must be provided via a needle or catheter, a process known as an infusion; however, some can also be given intramuscularly, epidurally, or using self-injectable devices. Multiple associated benefits of home infusion therapy coupled with the increasing immobility disorders are major growth drivers in the home infusion therapy market. Moreover, the higher rate of hospital-acquired infections and government regulation to encourage home therapy are further contemplated to boost the home infusion therapy market.

Multiple Associated Benefits of Home Infusion Therapy

Home infusion therapy offers a wider range of benefits to patients that encourage its adoption and thereby boost the home infusion therapy market. Studies demonstrate that patients are highly satisfied with home infusion therapy and that clinical results are more positive at home than in inpatient hospital settings. Depending on an individual's healthcare plan, it can be less expensive than receiving the same service at a hospital or clinic. Moreover, with 78% of customers indicating they would be very or somewhat inclined to employ alternative types of treatment, such as a clinician visiting the home, according to EverNorth Health Services, there has been an increase in the demand for more flexibility and choice in how care is given in recent years. The patients' inclination towards home care coupled with associated benefits is contemplated to propel the home infusion therapy market.

Increasing Immobility Disorders

The increasing cases of immobility disorders restraining physical movement indicate the growing demand for home infusion therapy. For instance, there are 1.3 billion persons who are severely disabled. This equates to 1 in 6 of us, or 16% of the world's population as per WHO updates in March 2023. According to the WHO, Accessible and inexpensive transit is 15 times more difficult to find for people with disabilities than it is for people without impairments. Therefore, these immobility disorders are expected to positively impact the home infusion therapy market as it offers a convenient at-home setting to the patients.

Need for Reducing Stays at Hospital

Numerous infections occur when a person stays longer at the hospital and home infusion therapy helps to reduce the infections acquired from the hospitals. According to the WHO, Seven patients in high-income nations and 15 patients in low- and middle-income countries are expected to contract at least one healthcare-associated infection (HAI) during their hospital stay per 100 patients in acute-care hospitals. Every ten people who are impacted will die as a result of their HAI, on average. Newborns and those in critical care are particularly vulnerable and the WHO 2022 study finds that over half of all instances of sepsis with organ failure are treated in adult intensive-care units and about one in four hospital-treated sepsis cases are related to medical care. These hospital-acquired infections pose a problem and therefore encourage the adoption of the home infusion therapy market.

Opportunities in the Market

The growth drivers mentioned above indicate an immense opportunity for the home infusion therapy market. Moreover, government regulations are also providing a growth opportunity in the home infusion therapy market. For instance, in 2021, the Centres for Medicare & Medicaid Services (CMS) passed new regulations that increased the coverage of home infusion therapy to cover a variety of related nursing and monitoring services in addition to the treatment itself. Moreover, Eitan Medical launched a new cutting-edge connected infusion multi-therapy ambulatory infusion system named Avoset™ to transform post-acute care and speciality infusion therapy. Additionally, the approvals of home infusion therapy by the authorities further propel the home infusion therapy market thereby providing an entrance opportunity. For instance, home infusion of anticancer therapy was approved by the ASCO board of directors in June 2020.

Restraints in the Market

There are a few complexities that are supposed to restrain the home infusion therapy market. For example, home infusion pharmacies, patients, doctors, hospital discharge planners, health insurance, and other parties must work closely together to complete the procedure because it can be a complex ecology. Disconnected data poses a significant problem because there are so many parties involved and it can lead to a variety of prescribing, administering, and/or coding problems. For instance, the physician normally submits prior authorization requests and prescription claims, but they go through the plan separately.

North America is projected to Grow Significantly

The North American region is anticipated to hold a significant share of the home infusion therapy market during the forecasted period. Various factors attributed to such a share are increasing immobility disorders, chronic diseases such as cancer, and the aging population along with the favorable government regulations to encourage home infusion therapy. For instance, 12.1 percent of adult U.S. citizens have a mobility impairment that makes walking and climbing stairs extremely difficult and 12.8 percent of adults in the United States struggle greatly with concentration, memory, and decision-making as per the recent CDC data. Moreover, the market players such as Baxter, and Braun Melsungen AG are further expected to propel the home infusion therapy market in the region.

Home Infusion Therapy Market Players

Baxter International is a US-based healthcare company with a portfolio including acute, nutritional, renal, hospital, and surgical care products. The company provides a portfolio of intravenous premixed medication and injectable drugs that are ready to fill patients' needs.

Ambulatory surgery centers, employed physician networks, two HMOs, and 15 hospitals are all part of McLaren Health Care. The Joint Commission (JCAHO) and the Community Health Accreditation Programme (CHAP) have both granted accreditation to McLaren's home infusion service.

Key Market Developments

  • In April 2022, AmericsourceBergon (AB) launched a program designed to help hospitals and health systems to launch home infusion service lines. It serves to strengthen program strategy, business operations, and logistics in home infusion therapy.
  • In August 2021, HealthIV, a new company focused on home infusion was launched to curb dehydration and hangovers. The company has a digital platform that enables users to book an online appointment for a nurse to come to the home for home infusion therapy.
  • In November 2021, The Hospital Clinic Haematology and Oncology Institute (ICMHO) launched an immunotherapy home infusion program for solid organ cancer patients and immunotherapy treatment. It carries out periodical lab tests, administers drugs at patients' homes, and health education.

Segmentation:

By Product

  • Infusion Pump Sets
  • Accessories and Consumables

By Application

  • Total Parenteral Nutrition
  • Anti-infective Therapy
  • Enteral Nutrition
  • Hydration Therapy
  • Chemotherapy
  • IVIg/Specialty Pharmaceuticals
  • Other Applications

By Route of Administration

  • Intramuscular
  • Subcutaneously
  • Epidural

By Geography

  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • The Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. HOME INFUSION THERAPY MARKET, BY PRODUCT

  • 5.1. Introduction
  • 5.2. Infusion Pump Sets
  • 5.3. Accessories and Consumables

6. HOME INFUSION THERAPY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Total Parenteral Nutrition
  • 6.3. Anti-infective Therapy
  • 6.4. Enteral Nutrition
  • 6.5. Hydration Therapy
  • 6.6. Chemotherapy
  • 6.7. IVIg/Specialty Pharmaceuticals
  • 6.8. Other Applications

7. HOME INFUSION THERAPY MARKET, BY ROUTE OF ADMINISTRATION

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Subcutaneously
  • 7.4. Epidural

8. HOME INFUSION THERAPY MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Braun Melsungen AG
  • 10.2. Baxter International
  • 10.3. Becton Dickinson and Companies
  • 10.4. Catholic Health Initiatives
  • 10.5. Community Surgical Supply
  • 10.6. Eli Lilly and Company
  • 10.7. Fresenius Kabi
  • 10.8. ICU Medical Inc.
  • 10.9. McKesson Medical-Surgical Inc.
  • 10.10. McLaren Health Care